Träger des Paul-Martini-Preises

Prof. Dr. med. Michael Platten (Mannheim/Germany)
Weitere Informationen
Prof. Dr. med. Andrea Ablasser (Lausanne/Switzerland)
Weitere Informationen
Prof. Dr. med. Stefan Fröhling (Heidelberg/Germany)
Prof. Dr. med. Hanno Glimm (Dresden/Germany)
Weitere Informationen
Prof. Dr. Dr. med. Thomas Thum (Hannover/Germany)
Weitere Informationen
Prof. Dr. Peter Kühnen (Berlin/Germany)
Weitere Informationen
Prof. Dr. med. Robert Zeiser (Freiburg/Germany)
  • Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD mutant leukemia cells. (Nature Medicine, 2018)
  • Oncogenic JAK2V617F causes PD-L 1 expression mediating immune-escape in myeloproliferative neoplasms. (Science Translational Medicine, 2018)
  • Neutrophils provide cellular communication between ileum and mensenteric lymph nodes at graft-versus-host disease onset. (Blood, 2018)
Weitere Informationen
Prof. Dr. med. Thorsten Zenz (Zürich/Switzerland)
  • Recurrent CDKN1B (p27) mutations in hairy cell leukemia (Blood, 2015)
  • BRAF inhibition in hairy cell leukemia with low-dose vemurafenib (Blood, 2016)
  • Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations (Blood, 2017)
  • Drug-perturbation-based stratification of blood cancer (Journal of Clinical Investigation, 2018)
Weitere Informationen
Prof. Dr. med. Harald Renz (Marburg/Germany)
Prof. Dr. rer. nat. Holger Garn (Marburg/Germany)
  • Allergen-Induced Asthmatic Responses Modified by a GATA3-Specific DNAzyme (New Engl J Med)
Weitere Informationen
Dr. med. Jan Krönke (Ulm/Germany)
  • Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells (Science 2014).
  • Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS (Nature 2015).
Weitere Informationen
Prof. Dr. med. Sonja Schrepfer (Hamburg/Germany)
  • Dichloroacetate prevents restenosis in preclinical animal models of vessel injury (Nature 2014).
  • SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts (Cell Stem Cell 2014)
  • Inducing myointimal hyperplasia versus atherosclerosis in mice: An introduction of two valid models (Journal of Visualized Experiments 2014).
  • Human internal mammary artery (IMA) transplantation and stenting: a human model to study the development of in-stent restenosis (Journal of Visualized Experiments 2012).
Weitere Informationen
Prof. Dr. med. Matthias Tschöp (Munich/Germany)
  • Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys and humans. (Science Translational Medicine 2013)
  • Duodenal nutrient exclusion improves metabolic syndrome and stimulates villus hyperplasia. (Gut 2013)
  • GLP-1R agonism enhances adjustable gastric banding in diet-induced obese rats. (Diabetes 2013)
  • Targeted estrogen delivery reverses the metabolic syndrome. (Nature Medicine 2012)
Weitere Informationen
Prof. Dr. med. Andreas Engert (Cologne/Germany)
  • Reduced treatment intensity in patients with early stage Hodgkin's lymphoma. (New England Journal of Medicine 2010)
  • Reduced intensity of chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. (The Lancet 2012)
  • Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. (Journal of Clinical Oncology 2010)
  • Brentuximab vedotin for relapsed or refractory CD30-positive hematologic malignancies – the GHSG experience. (Blood 2012)
Weitere Informationen
PD Dr. med. Jan Wehkamp (Stuttgart/Germany)
  • Reduction of disulphide bonds unmasks potent antimicrobial activity of human ß-defensin 1 (Nature 2011)
Prof. Dr. med. Stephan Stilgenbauer (Ulm/Germany)
Prof. Dr. med. Michael Hallek (Köln/Germany)
  • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial (The Lancet 2010)
Weitere Informationen
PD Dr. med. Kaan Boztug (Wien/Austria)
Prof. Dr. med. Christoph Klein (München/Germany)
  • Stem-Cell Gene Therapy for the Wiskott-Aldrich Syndrome (New England Journal of Medicine 2010;363:1918-27)
Weitere Informationen
PD Dr. med. Jürgen Ruland
  • Adjuvanticity of a synthetic cord factoranalogue for subunit Mycobacterium tuberculosis vaccination requires FcRy-Syk–Card9–dependent innate immune activation (Journal of Experimental Medicine 2009)
  • Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells (Journal of Experimental Medicine 2009)
  • Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence (Nature 2009)
  • Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin- 1ß production (Nature Immunology 2010)
Prof. Dr. med. Veit Hornung
  • Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization (Nature Immunology 2008)
  • AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC (Nature 2009)
  • RIG-I-dependent sensing of Poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate (Nature Immunology 2009)
  • Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin-1ß production (Nature Immunology 2010)
Weitere Informationen

Preisträger vor 2011